The effective tax rate on a non-GAAP basis was 12.6 percent in the fourth quarter of 2019, compared with 15.6 percent in the fourth quarter of 2018. Retevmo generated U.S. revenue of $99.4 million and revenue of $15.4 million outside the U.S. for the full year of 2021. Analysis of Revenues Eli Lilly & Co. (NYSE:LLY) The Company Profile Analysis of Revenues Revenues as Reported Johnson & Johnson (NYSE:JNJ), Analysis of Revenues Merck & Co. Inc. (NYSE:MRK), Analysis of Revenues AbbVie Inc. (NYSE:ABBV), Analysis of Revenues Thermo Fisher Scientific Inc. (NYSE:TMO), Analysis of Revenues The decrease in gross margin percent was primarily due to unfavorable product mix, the unfavorable effect of foreign exchange rates on international inventories sold, and the impact of lower realized prices on revenue. For the fourth quarter of 2018, amount relates to adjustments to the 2017 Toll Tax for U.S. tax reform proposed regulations and tax expenses associated with the separation of Elanco. Actual results may differ materially due to various factors. Gross margin as a percent of revenue for the full year of 2021 was 77.4 percent, compared with 79.3 percent for the full year of 2020. (a) For the fourth quarter of 2019, amount relates to a tax benefit from a capital loss on the disposition of subsidiary stock. Exclude adjustments to prior period estimates for asset impairment and severance costs. F-LLY. Eli Lilly Revenue Boosted by New Drug Sales - WSJ Exclude COVID-19 antibodies inventory charge and asset impairment, restructuring and other special charges primarily related to an intangible asset impairment resulting from the sale of rights to Qbrexza, the impairment of a contract-based intangible asset from our acquisition of. Operating Results (Unaudited) REPORTED, (Dollars in millions, except per share data), Earnings from continuing operations - diluted, Earnings from discontinued operations - diluted, Weighted-average shares outstanding (thousands) - diluted, Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information (Unaudited). Certain financial information for 2019 and 2018 is presented on both a reported and a non-GAAP basis. For the full year of 2019, Olumiant generated worldwide revenue of $426.9 million, an increase of $224.4 million compared with the full year 2018. For the full year of 2021, worldwide Alimta revenue decreased 12 percent, to $2.061 billion compared with the full year of 2020. Learn more about how Statista can support your business. specialcharges, Weighted-average shares outstanding (thousands) For the fourth quarter of 2019, worldwide Humulin revenue increased 3 percent compared with the fourth quarter of 2018, to $348.0 million. NYSE | Forteo revenue outside the U.S. was $360.3 million, a 33 percent decrease, driven by decreased volume and, to a lesser extent, lower realized prices. For the full year of 2021, Olumiant generated worldwide revenue of $1.115 billion, an increase of 75 percentcompared with the full year of 2020. [Online]. Its products are sold in approximately 125 countries. The effective tax rate on a non-GAAP basis was 10.3 percent in the fourth quarter of 2021, compared with 13.1 percent in the fourth quarter of 2020. Eli Lilly Says Alzheimer's Treatment Slows Cognitive Decline U.S. revenue was $876.2 million, an increase of 41 percent, driven by higher realized prices and increased demand. This statistic was assembled from several editions of Eli Lilly's annual report. (b) For 2019, amount relates to a tax benefit from a capital loss on the disposition of subsidiary stock. Operating income in 2019 increased 41 percent compared with 2018 to $4.974 billion, driven primarily by lower acquired in-process research and development and, to a lesser extent, higher gross margin, partially offset by higher operating expenses. "Eli Lilly and Company's top products based on revenue in 2021 and 2022 (in million U.S. Revenue outside the U.S. increased 5 percent to $9.597 billion, due to increased volume for key growth products, including Trulicity, Olumiant, Taltz, Jardiance and Verzenio. The table above reflects only line items with non-GAAP adjustments. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. Revenue in Q4 2022 decreased 9%. Eli Lilly and Company Employment Information, (Dollars in millions, except per share data), Acquired in-process share data), Asset impairment, restructuring and U.S. revenue was $13.0 million. As soon as this statistic is updated, you will immediately be notified via e-mail. The ideal entry-level account for individual users. Revenue outside the U.S. increased 3 percent, to $107.9 million, due to higher realized prices and increased volume, partially offset by the unfavorable impact of foreign exchange rates. Among other things, they may help investors evaluate the company's ongoing operations. For the fourth quarter of 2021, worldwide Verzenio revenue increased 43 percent compared with the fourth quarter of 2020, to $404.1 million. Eli Lilly top products by revenue 2021-2022 | Statista Management uses these non-GAAP measures internally to evaluate the performance of the business, including to allocate resources and to evaluate results relative to incentive compensation targets. On a non-GAAP basis, in the fourth quarter of 2019, net income increased 26 percent, to $1.583 billion, while earnings per share increased 31 percent, to $1.73, compared with $1.258 billion and $1.32, respectively, in the fourth quarter of 2018. For the full year of 2021, the company's Tyvyt revenue in China was $418.1 million, an increase of 35 percent compared with the full year of 2020. In 2018, the company recognized asset impairment, restructuring, and other special charges of $266.9 million primarily associated with asset impairments related to the sale of the Posilac (rbST) brand and its Augusta, Georgia manufacturing site. In 2021, the company recognized acquired in-process research and development charges of $874.9 million resulting from business development transactions compared with $660.4 million in 2020. The increase in U.S. revenue was negatively impacted by lower realized prices for several products, primarily Trulicity. U.S. revenue was $87.9million, an increase of 9 percent, primarily driven by increased demand. Activist investor NexPoint threatens to block Paratek's $462M sale. Club name Eli Lilly (LLY) and Novo Nordisk (NVO) are expected to remain the industry leaders, with a combined market share of 82%, despite growing competition. Authentic virus analysis of bebtelovimab confirm earlier pseudovirus findings, which demonstrate. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. For the fourth quarter of 2019, worldwide Cialis revenue decreased 44 percent compared with the fourth quarter of 2018, to $197.8 million. For the full year of 2021, the company's worldwide Jardiance revenue was $1.491 billion, an increase of 29 percent compared with the full year of 2020. Gross margin increased 7 percent, to $4.831 billion, in the fourth quarter of 2019 compared with the fourth quarter of 2018. Alimta (pemetrexed disodium, Lilly)Baqsimi (glucagon, Lilly) Basaglar (insulin glargine injection, Lilly) Cialis (tadalafil, Lilly)Cyramza (ramucirumab, Lilly) Emgality (galcanezumab-gnlm, Lilly) Forteo (teriparatide of recombinant DNA origin injection, Lilly) Glyxambi (empagliflozin/linagliptin, Boehringer Ingelheim) Humalog (insulin lispro injection of recombinant DNA origin, Lilly) Humulin (human insulin of recombinant DNA origin, Lilly) Jardiance (empagliflozin, Boehringer Ingelheim) Lartruvo (olaratumab, Lilly) Olumiant (baricitinib, Lilly) Posilac (recombinant bovine somatotropin, Lilly) QBREXZA (Glycopyrronium cloth, Dermira) REYVOW (lasmiditan, Lilly) Strattera (atomoxetine, Lilly) Synjardy (empagliflozin/metformin, Boehringer Ingelheim) Taltz (ixekizumab, Lilly) Trajenta(linagliptin, Boehringer Ingelheim) Trijardy XR (empagliflozin/linagliptin/metformin hydrochloride extended release tablets, Boehringer Ingelheim) Trulicity (dulaglutide, Lilly) Tyvyt (sintilimab injection, Lilly) Verzenio (abemaciclib, Lilly) Vitrakvi(larotrectinib, Bayer). The increase in net income in the fourth quarter of 2019 was primarily driven by higher operating income and higher other income, partially offset by higher income taxes. Revenue outside the U.S. was $670.4 million, an increase of 34 percent, primarily driven by increased volume. Revenue in the U.S. increased 7 percent, to $3.519 billion, as increased volume of 8 percent was partially offset by lower realized prices. In the fourth quarter of 2019, the company recognized asset impairment, restructuring and other special charges of $151.7 million. Exclude amortization of intangibles primarily associated with costs of marketed products acquired or licensed from third parties. Copyright 2023 Eli Lilly and Company. Lilly Highlights Innovation-based Growth - Eli Lilly and Company In both trials, there was no significant change from baseline to week 12 in exercise ability with Jardiance versus placebo, as measured by the six-minute walk test which was the primary endpoint of the studies. Adjustments to certain GAAP reported measures for the twelve months ended December 31, 2018, include the following: Exclude costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than a business combination. Revenue outside the U.S. was $266.1 million, an increase of 36 percent, driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and lower realized prices. For the full year of 2021, worldwide Forteo revenue decreased 23 percent to $801.9 million compared with the full year of 2020. Revenue outside of the U.S. was $304.2 million, an increase of 8 percent, primarily driven by increased volume. For the full year 2019, worldwide Trulicity revenue was $4.128 billion, an increase of 29 percent compared with the full year 2018. Some numbers in this press release may not add due to rounding. Eli Lilly: Great Business And Growth, But Fully Priced U.S. revenue increased 36 percent, to $157.5 million, driven by increased demand. Other income (expense) exclude the gain on sale of the company's antibiotics business in China as well as charges related to the repurchase of debt. Lilly Reports Second-Quarter Financial Results, Highlights Momentum of New Medicines and Pipeline Advancements | Eli Lilly and Company Skip to main navigation Skip to main content Email Alerts News Lilly.com Menu Menu Close Close Stock Info Expand mega menu Expand submenu Left Back Stock Info The increase in net income was driven primarily by lower tax expense and higher other income, partially offset by lower operating income. statistic alerts) please log in with your personal account. Eli Lilly | LLY Stock Price, Company Overview & News - Forbes LLY Sales vs. its Competitors Q1 2023. Revenue outside the U.S. increased 28 percent, to $63.7million, driven by increased volume, partially offset by lower realized prices and the unfavorable impact of foreign exchange rates. The increase in U.S. volume was driven by certain key growth products, including Trulicity, Taltz, Jardiance, Verzenio and Olumiant. The increases in net income and EPS were driven by higher operating income. to incorporate the statistic into your presentation at any time. Solid First-Quarter Financial Results Reflect Lilly's Continued As a Premium user you get access to background information and details about the release of this statistic. Morgan Stanley raised its price . In the fourth quarter of 2021, the company recognized asset impairment, restructuring and other special charges of $104.5 million primarily related to impairment of an intangible asset from our acquisition of Loxo Oncology. For the full year of 2021, worldwide Trulicity revenue was $6.472 billion, an increase of 28 percent compared with the full year of 2020. Key growth products, consisting of Trulicity, Taltz, Verzenio, Jardiance, Olumiant, Emgality, Retevmo, Cyramza and Tyvyt, contributed 14 percentage points of revenue growth and represented 61 percent of total revenue for the fourth quarter of 2021, excluding COVID-19 antibodies. Revenue outside the U.S. decreased 7 percent, to $294.7 million, primarily driven by decreased volume and, to a lesser extent, the unfavorable impact of foreign exchange rates. Charge related to repurchase of higher-cost debt, Net gains on investments in equity securities, (b)COVID-19 antibodies include sales for bamlanivimab administered alone as well as sales for bamlanivimab and etesevimab administered together and were made pursuant to Emergency Use Authorizations (EUA), (c)Jardiance includes Glyxambi, Synjardy, and Trijardy XR, (d)Olumiant includes salesof baricitinib that were made pursuant to EUA. For the fourth quarter of 2021, worldwide Cyramza revenue decreased 5 percent compared with the fourth quarter of 2020, to $270.4million. Increased volume worldwide was partially driven by utilization of Olumiant for the treatment of hospitalized patients with COVID-19. Guidant Corporation -- Company History Revenue outside the U.S. was $178.6million, a decrease of 1 percent, driven by the unfavorable impact of foreign exchange rates and lower realized prices, largely offset by increased volume. Research and development expenses are still expected to be in the range of $5.6 billion to $5.9 billion. Except as is required by law, the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release. Credit: Momoneymoproblemz / Wikimedia. The 2018 income tax benefit was primarily due to U.S. tax reform adjustments of $344.6 million. Lilly reports as cost of sales payments made to Boehringer Ingelheim for royalties. There can be no guarantees that pipeline products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. U.S. revenue increased 35 percent to $834.9 million, driven by increased demand. The increase in other income (expense) was primarily driven by income from patent settlements in Europe for Alimta in 2021. U.S. revenue was $22.4 million in the fourth quarter, an 87 percent decrease compared with the fourth quarter of 2018, driven by decreased demand due to generic competition. INDIANAPOLIS, Feb. 3, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced financial results for the fourth quarter and full year of 2021 today. Eli Lilly to buy Versanis for up to $1.93 billion in obesity drugs push for adults with heart failure independent of left ventricular ejection fraction. For the fourth quarter of 2021, worldwide Humalog revenue decreased 16 percent compared with the fourth quarter of 2020, to $601.7 million. Call (800) 545-5979, Lilly Reports Strong Fourth-Quarter and Full-Year 2019 Financial Results, Updates 2020 Guidance for Pending Dermira Acquisition, Impact of reduced shares outstanding for non-GAAP reporting, http://www.prnewswire.com/news-releases/lilly-reports-strong-fourth-quarter-and-full-year-2019-financial-results-updates-2020-guidance-for-pending-dermira-acquisition-300996069.html. Headquarter Indianapolis, Indiana, The United States Headcount Approximately 36,190 (March, 2022) CEO Mr. David A. Ricks Overall Revenue US$ 28,318.4 Mn in 2021 Products Diabetes and other endocrinology products, Immunology products, Neuroscience products, Oncology products, Other products Brands Eli Lilly & Corporation's Revenue by Region The company sells most of its products worldwide. Excludes charge related to the repurchase of higher-cost debt. The increase in other income was primarily driven by the gain on the sale of the company's antibiotics business in China and higher net gains on investment securities, partially offset by a charge related to the repurchase of debt. Eli Lilly And Revenue Growth Rates (LLY), Current and - CSIMarket Available: https://www.statista.com/statistics/278214/eli-lilly-and-companys-top-products-based-on-revenue/, Eli Lilly and Company's top products based on revenue in 2021 and 2022, Immediate access to statistics, forecasts & reports, Top 10 biotech and pharmaceutical companies based on market cap 2022, Projection of top 2023 pharma and biotech launches by revenue 2028, Projected top pharmaceutical companies based on new sales 2023, Forecast sales of top psoriasis treatments worldwide 2019-2026, Eli Lilly income before income taxes 2013-2022, Eli Lilly's total revenue by region 2016-2022, Eli Lilly's total revenue by segment 2020-2022, Eli Lilly and Company's top products based on revenue 2021-2022, Boehringer Ingelheim's total revenue 2007-2022, Eli Lilly's research and development expenditure 2007-2022, Eli Lilly's R&D expenditure as a share of revenue 2010-2022, Global top pharmaceutical companies based on R&D spending 2026, Number of pharmaceuticals on China's national reimbursement drug list, Boehringer Ingelheim's top self-medication drugs revenues 2008-2016, Eli Lilly's total revenue per employee 2013-2019, U.S. human and veterinary pharmaceuticals - R&D spending 2017, Spending growth of top pharmaceutical therapeutic classes by CAGR 2014-2018, Pharmaceutical industry: global breakdown in the sale of new drugs 2004-2022, Number of approved ANDAs in U.S. 2009-2022, Top specialty drug pharmacies in the U.S. by revenue 2021, Definition of specialty drugs by PBMs and pharmacy executives 2011, Number of ANDA approvals in U.S. 2015-2017, by type, Gilead Sciences' top products based on revenue 2020-2022, Patent applications for genetic drugs worldwide 2010, Members of EFPIA's pharmaceutical exports and imports 1990-2022, Top specialty drug pharmacies in the U.S. based on market share 2021, Volume of exports of Chinese medicinal plants from China H1 2020, by ingredients, Leading immunostimulant brands in Russia Q1 2020, by sales share, Eli Lilly and Company's top products based on revenue in 2021 and 2022 (in million U.S. dollars), Find your information in our database containing over 20,000 reports, second top seller of anti-diabetic pharmaceuticals. For the full year of 2021, worldwide Emgality revenue was $577.2 million, an increase of 59 percent compared with the full year of 2020. The company now anticipates 2020 revenue between $23.7 billion and $24.2 billion. This change lagged the S&P 500's 0.4% gain on the day. For the full year of 2021, the effective tax rate was 9.3 percent, compared with an effective tax rate of 14.3 percent for the full year of 2020. In addition, Eli Lilly registered a decline of -4.1% in the revenue generated by insulin products compared to 2019. Outside the U.S., Retevmo, which launched during the second quarter of 2021, generated revenue of $7.2million in the fourth quarter of 2021. The increases in net income and EPS were primarily driven by higher operating income. Due to competitive pressures, the company expects a continued price decline for Humalog in the U.S. For the fourth quarter of 2021, worldwide Taltz revenue increased 31 percent compared with the fourth quarter of 2020, to $647.4million. Revenue outside the U.S. increased 42 percent, to $972.7 million, primarily driven by increased volume, partially offset by the unfavorable impact of foreign exchange rates and, to a lesser extent, lower realized prices. Revenue outside of the U.S. increased 75 percent to $515.0 million, driven by increased volume. U.S. revenue increased 3 percent, to $240.1 million, driven by increased volume and higher realized prices due to changes in estimates for rebates and discounts. Track the evolution of an ETF, mutual fund, or stock over time, revealing invaluable insights that could drive your future investment strategies. Exclude costs associated with upfront payments for acquired in-process research and development projects acquired in a transaction other than abusiness combination. U.S. revenue decreased 1 percent, to $313.7million, primarily driven by lower realized prices due to changes in estimates for rebates and discounts, partially offset by increased demand. Based on top-line efficacy results from two pivotal Phase 3 trials (SLE-BRAVE-I and II), the company has decided to discontinue the Phase 3 development program for Olumiant in adults with active systemic lupus erythematosus. Jun . USD | The table above reflects only line items with non-GAAP adjustments. Marketing, selling and administrative expenses increased 5 percent to $6.432 billion, primarily due to increased marketing costs to continue to drive growth for key products, investment in preparation for new launches, and lower marketing activities in 2020 as a result of pandemic-related spending reductions. The company's highest selling drugs for the year were Humalog (insulin) with $2.7 billion in sales, erectile dysfunction drug Cialis with $2.4 billion, and lung cancer drug Alimta with $2.2 billion in sales. "Lilly is in the early phase of an exciting period of growth for the company. U.S. Forteo revenue for 2019 was $645.5 million, a 15 percent decrease primarily driven by decreased demand. Historical Insights: The Key to Future Strategies. In 2018, the company recognized acquired in-process research and development charges of $1.984 billion, primarily related to the acquisition of ARMO BioSciences and the business development transaction with Dicerna Pharmaceuticals. The increase in operating income was primarily driven by lower acquired in-process research and development charges and higher gross margin, partially offset by higher research and development expenses. Order Reprints. Operating income in 2021 increased 5 percent compared with 2020 to $6.357 billion, as higher gross margin was partially offset by higher operating expenses, higher acquired in-process research and development charges, and higher asset impairment, restructuring and other special charges. The increase was primarily driven by higher development expenses for late-stage assets. Revenue outside the U.S. increased 28 percent, to $683.5 million, primarily driven by increased volume. A paid subscription is required for full access. U.S. revenue was $1.017 billion, an increase of 38 percent primarily driven by increased demand, partially offset by lower realized prices. This statistic is not included in your account. Revenue outside the U.S. was $114.9 million, an increase of 74 percent compared with the fourth quarter of 2018, driven by increased demand, partially offset by lower realized prices and the unfavorable impact of foreign exchange rates. In addition, revenue outside the U.S. benefited from a milestone from Bayer Consumer Care AG resulting from its exclusive development and commercialization license for Vitrakvi. For further detail on non-GAAP measures, see the reconciliation below as well as the "Reconciliation of GAAP Reported to Selected Non-GAAP Adjusted Information" table later in this press release. Weighted-average shares outstanding (thousands), The company uses non-GAAP financial measures that differ from financial statements reported in conformity with, Adjustments to certain GAAP reported measures for the three months ended. U.S. revenue was $121.0 million, an increase of 25 percent, driven by higher realized prices and increased demand. "Lilly had a remarkable year of growth and pipeline success in 2021, despite the continued hardships from the pandemic," said David A. Ricks, Lilly's chair and CEO. U.S. Humalog revenue for 2019 was $1.670 billion, a 7 percent decrease, primarily driven by lower realized prices and decreased demand. ", In the fourth quarter of 2021, worldwide revenue was, Total operating expenses in the fourth quarter of 2021, increased 5 percent to, In the fourth quarter of 2021, the company recognized acquired in-process research and development charges of, In the fourth quarter of 2021, the company recognized asset impairment, restructuring and other special charges of, Operating income in the fourth quarter of 2021 was, In the fourth quarter of 2021, net income and EPS both decreased 18 percent, to, On a non-GAAP basis, fourth quarter of 2021 gross margin increased 4 percent, to, Operating income on a non-GAAP basis increased, Other income (expense) on a non-GAAP basis was expense of, On a non-GAAP basis, in the fourth quarter of 2021 net income and EPS both increased 8 percent, to, For the full year of 2021, worldwide revenue increased 15 percent to, Total operating expenses increased 10 percent to, In 2021, the company recognized acquired in-process research and development charges of, In 2021, the company recognized asset impairment, restructuring and other special charges of, Operating income in 2021 increased 5 percent compared with 2020 to, For the full year of 2021, net income and EPS both decreased 10 percent, to, On a non-GAAP basis for the full year of 2021, gross m. argin increased 13 percent, to$21.914 billioncompared with the full year of 2020. The decrease in gross margin percent was driven by higher sales of COVID-19 antibodies. The non-GAAP measures are presented to provide additional insights into the underlying trends in the company's business. U.S. revenue was $154.9 million. In the fourth quarter of 2021, net income and EPS both decreased 18 percent, to $1.726billion and $1.90, compared with $2.117billion and $2.32, respectively, in the fourth quarter of 2020. Numbers may not add due to rounding. Overview and forecasts on trending topics, Industry and market insights and forecasts, Key figures and rankings about companies and products, Consumer and brand insights and preferences in various industries, Detailed information about political and social topics, All key figures about countries and regions, Market forecast and expert KPIs for 1000+ markets in 190+ countries & territories, Insights on consumer attitudes and behavior worldwide, Business information on 70m+ public and private companies, Detailed information for 39,000+ online stores and marketplaces. Building on its historic foundation of helping people with diabetes, Lilly is expanding its strategic focus to breakthrough medications that disrupt the disease cascade caused by obesity and type 2 diabetes progression, highlighted by tirzepatide and supported by several early-phase incretin assets. except per share data), Acquired in-process For the full year of 2019, Emgality generated worldwide revenue of $162.5 million. U.S. revenue was $252.8 million, an increaseof 34 percent, driven by increased demand, partially offset by lower realized prices. NM - not meaningful. On a non-GAAP basis for the full year 2019, gross margin increased 4 percent, to $17.888 billion compared with the full year 2018. These costs were related to business development transactions with Foghorn Therapeutics Inc., QILURegorTherapeuticsInc.,and. Adjustments to certain GAAP reported measures for the three months ended December 31, 2020, include the following: Acquired in-process research and Other income was $262.9 million in the fourth quarter of 2019, compared with $31.4 million in the fourth quarter of 2018. The company's 2022 financial guidance reflects adjustments shown in the reconciliation table below. As the year wraps up, Eli Lilly has set high ambitions for the year ahead. The decrease in gross margin percent was driven by higher sales of COVID-19 antibodies. Revenue is an extremely important metric when analyzing a company. Pharma giant Eli Lilly & Company ( LLY 2.01%) has performed splendidly in the past year, leaving both the broader market and the pharmaceutical industry in the dust. Other income on a non-GAAP basis was $205.6 million in the fourth quarter of 2019, compared with $31.4 million in the fourth quarter of 2018. The lower effective tax rate in the fourth quarter of 2021 was primarily driven by net discrete tax items in both periods, as well as the tax benefit related to net losses on investments in equity securities compared with higher tax expense related to net gains on investments in equity securities in the fourth quarter of 2020. Asset impairment, restructuring and other special charges exclude charges primarily associated with our decision to close and sell a research and development facility located in the United Kingdom, as well as severance costs incurred as a result of actions taken to reduce the company's cost structure. Some numbers in this press release may not add due to rounding. Key Dates: 1876: Colonel Eli Lilly starts making ethical drugs in Indianapolis. Colonel Lilly was 38 . The company's worldwide Jardiance revenue during the fourth quarter of 2019 was $268.0 million, an increase of 39 percent compared with the fourth quarter of 2018. Gross margin as a percent of revenue was 74.4 percent, a decrease of 2.5 percentage points compared to the fourth quarter of 2020. Jun 28, 2023 02:03pm. INDIANAPOLIS, April 27, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the first quarter of 2021.